Physician Search
 |
 |
| Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Multiple Cancer Types
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone
(fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of
children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are
unable to receive additional anthracyclines, or in 2nd relapse.
(fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of
children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are
unable to receive additional anthracyclines, or in 2nd relapse.
Pediatric Leukemia,
Pediatrics
III
Zarnegar-Lumley, Sara
NCT05183035
VICCPED2237
DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
Multiple Cancer Types
This is a Phase 1b/2, multi-center, open label umbrella study of patients 12 years of age
with recurrent or progressive solid tumors with alterations in the key proteins of the
RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.
with recurrent or progressive solid tumors with alterations in the key proteins of the
RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.
Miscellaneous,
Phase I
I/II
Berlin, Jordan
NCT04985604
VICCMD2142
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Melanoma
Melanoma
Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and
safety/tolerability of ceralasertib, when administered as monotherapy and in combination with
durvalumab in participants with unresectable or advanced melanoma and primary or secondary
resistance to PD-(L)1 inhibition.
safety/tolerability of ceralasertib, when administered as monotherapy and in combination with
durvalumab in participants with unresectable or advanced melanoma and primary or secondary
resistance to PD-(L)1 inhibition.
Melanoma
II
Johnson, Douglas
NCT05061134
VICCMEL2177
Strata PATH (Precision Indications for Approved Therapies)
Miscellaneous
Miscellaneous
StrataPATH is a non-randomized, open-label trial designed to explore efficacy and safety of
multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided
patient populations.
multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided
patient populations.
Miscellaneous
II
Berlin, Jordan
NCT05097599
VICCMD2205
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination with Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
Leukemia
Leukemia
This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called fms-like tyrosine kinase 3 (FLT3). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is an enzyme inhibitor. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Venetoclax and decitabine are commonly given together for older patients with AML ASTX727 (a pill form of decitabine + cedazuridine) has been found to be equal to decitabine (given intravenously), and this part of the study is to confirm that venetoclax and ASTX727 is as safe as venetoclax and decitabine given intravenously. This study allows for lowering doses of study drugs to assure the dose chosen for the randomized study (second portion of this trial) is safe and tolerable for people. Giving ASTX727 in combination with venetoclax may help in the treatment of patients with higher-risk acute myeloid leukemia.
Leukemia
I/II
Savona, Michael
NCT04817241
VICCNCIHEM10417
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
Head/Neck
Head/Neck
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and
fibrosis (LEF) in head and neck cancer (HNC) survivors.
fibrosis (LEF) in head and neck cancer (HNC) survivors.
Head/Neck
N/A
Murphy, Barbara
NCT04797390
VICCHN2111
Avelumab or Hydroxychloroquine with or without Palbociclib for the Treatment of Stage II-III Breast Cancer, PALAVY Study
Breast
Breast
This phase II trial investigates the effect of avelumab or hydroxychloroquine sulfate with or without palbociclib in treating patients with stage II-III breast cancer that is positive for disseminated tumor cells (DTCs) after curative therapy. DTCs are breast cancer cells that are asleep (dormant) in the bone marrow. There are multiple ways in which these cells stay alive, and three of these mechanisms are inhibited by the drugs in this trial. First, dormant cancer cells need a protein signal pathway involving CDK 4/6 to start dividing once they wake up in order to survive as an active cancer cell. Palbociclib works by blocking the CDK 4/6 protein and by doing so may limit the dormant cancer cell from being able to survive. In addition, palbociclib may also help both of the other drugs in the trial to work better. Second, dormant cancer cells also use a process called autophagy to generate their own nutrition, which can allow them to stay asleep. Hydroxychloroquine has been shown to block autophagy, which leads to starvation of the cells. Third, dormant cancer cells are able to hide from the bodys immune system. The immune system sends a type of cell called T cells throughout the body to detect and fight infections and diseasesincluding cancers. One way the immune system controls the activity of T cells is through the PD-1/PD-L1 (programmed cell death protein-1) pathway. However, some cancer cells hide from T-cell attack by taking control of the PD-1/PD-L1 interaction and this stops T cells from attacking cancer cells. Avelumab is an antibody designed to block the PD-1/PD-L1 pathway and helps the immune system in detecting and fighting dormant cancer cells. Because palbociclib, hydroxychloroquine, and avelumab work on the mechanisms that keep the dormant cells alive, taking one or a combination of these drugs may be able to eliminate DTCs.
Breast
II
Reid, Sonya
NCT04841148
VICCBRE2161
A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis
Multiple Cancer Types
This is a global, Phase 1/2, multicenter, open-label study to evaluate the safety and
efficacy of selinexor plus ruxolitinib in treatment nave myelofibrosis (MF) participants.
The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study
will be dose escalation (non-randomized dose finding study) to determine the maximum
tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary
efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose
expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the
safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy
exploration) of the study will include MF participants who are treatment nave randomized 1:1
to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib
monotherapy.
efficacy of selinexor plus ruxolitinib in treatment nave myelofibrosis (MF) participants.
The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study
will be dose escalation (non-randomized dose finding study) to determine the maximum
tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary
efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose
expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the
safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy
exploration) of the study will include MF participants who are treatment nave randomized 1:1
to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib
monotherapy.
Hematologic,
Phase I
I/II
Mohan, Sanjay
NCT04562389
VICCHEMP2130
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
Multiple Cancer Types
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of
escalating doses of belzutifan as second line positive (2L+) treatment in participants with
advanced clear cell renal cell carcinoma (ccRCC).
escalating doses of belzutifan as second line positive (2L+) treatment in participants with
advanced clear cell renal cell carcinoma (ccRCC).
Kidney (Renal Cell),
Phase I
I
Beckermann, Kathryn
NCT04846920
VICCUROP2127
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and
tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV
as monotherapy and in combination with pembrolizumab in patients with recurrent, locally
advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck,
cervical, anal, vulvar, or penile cancer.
tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV
as monotherapy and in combination with pembrolizumab in patients with recurrent, locally
advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck,
cervical, anal, vulvar, or penile cancer.
Not Available
I/II
Iams, Wade
NCT05357898
VICCPHI2264
